The Bayer Pharmaceuticals Product Supply team is responsible for planning, sourcing, manufacturing and delivering pharmaceuticals and medical devices for patients and healthcare professionals around the world. The team plays an important role when it comes to sustainable resource and supply chain management. It has a strong influence on the entire organization’s day-to-day operations and is the driver for adopting more sustainable practices across Bayer Pharmaceuticals.
Our priorities for reducing the environmental impact in Pharmaceuticals Product Supply
We have ambitious sustainability goals, which build on the team’s foundation of decades of increasingly sustainable practices. As we look ahead, we are stepping up our efforts in direct support of our company-wide 2030 Sustainability Commitments, and are setting new parameters as we strive to advance a carbon-zero future for the pharmaceutical business. As a global company, we have the ability to influence how pharmaceutical manufacturing and supply networks can operate even more sustainable.
Key areas where we aim to reduce our greenhouse gas emissions by 2030:
Bayer-wide external suppliers and services: Emission reduction by engaging with our suppliers
Bayer-wide direct and indirect emissions from our operations: 100 percent carbon-neutral operations through energy efficiencies, shift to green energy, and compensation
One way we are meeting our commitment to reducing our impact on the environment is by using our resources more sustainably and efficiently. Cross-functional teams are working intensely together with global experts on the roadmaps toward 2030 goals, analyzing energy flows, switching to 100 percent renewable electricity, reducing materials and energy consumption in our manufacturing processes, and optimizing our logistics network, to enable us to ensure access to Bayer products, sustainably.
With our ambitious sustainability goals, we want to reduce the environmental impact of our own operations and supply networks. Thereby we aim to generate a positive effect for society and the environment.
Dr. Holger Weintritt
Member of the Executive Leadership Team and Head of Product Supply for the Pharmaceuticals Division of Bayer AG
Demonstrating transparency in our impact measurement and reporting
For decades, Bayer has been active in climate protection, and we will continue to prioritize actions to combat climate change and protect the environment.
The entire Bayer organization is dedicated to Science Based Targets – an initiative implemented by the United Nations Carbon Transparency Initiative (CDP), European Pack, International Center of Wealth (WRI) and World Wide Fund for Nature (WWF). As part of this initiative, more than 700 businesses, including Bayer, have pledged to take meaningful climate action to set emissions reduction targets in order to keep the global temperature increase below 2°C.
The Bayer Pharmaceuticals division is equally committed to meeting these targets and ensuring full transparency through the approved protocols for reporting our impacts as part of the Bayer Sustainability Report. Positive impacts in sustainability begin with us, and we look forward to continuing to share our progress.
By 2030, we are committed to providing 100 million women in low- and middle-income countries with access to modern contraception.
HEALTH FOR ALL
Fighting Neglected Tropical Diseases
Together with the World Health Organization (WHO) and other partners, we are improving public health in some of the most underserved regions of the world by working to eliminate the impact of the most devastating Neglected Tropical Diseases (NTDs) by 2030.
HEALTH FOR ALL
Moving Non-Communicable Disease Care Forward
In partnership with health specialists and stakeholders around the world, we seek to sustainably improve local prevention, management and treatment standards of cardiovascular and other non-communicable diseases.
HEALTH FOR ALL
Strengthening Healthcare Access
In collaboration with our partners, we aim to support more patients in low- and middle-income countries (LMICs) to access our medicines, for a healthier global society.